Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $24.00.

Several research analysts have weighed in on IOVA shares. StockNews.com upgraded shares of Iovance Biotherapeutics to a “sell” rating in a research report on Monday, August 12th. Piper Sandler cut Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $19.00 to $10.00 in a report on Monday, July 29th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of Iovance Biotherapeutics in a report on Monday, August 12th. Finally, JMP Securities lowered their target price on Iovance Biotherapeutics from $25.00 to $23.00 and set a “market outperform” rating on the stock in a report on Thursday, June 20th.

Institutional Trading of Iovance Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IOVA. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Iovance Biotherapeutics during the 2nd quarter worth about $107,000. Perceptive Advisors LLC boosted its position in Iovance Biotherapeutics by 34.6% during the second quarter. Perceptive Advisors LLC now owns 25,933,142 shares of the biotechnology company’s stock worth $207,984,000 after acquiring an additional 6,660,151 shares during the last quarter. Cim Investment Management Inc. grew its stake in Iovance Biotherapeutics by 126.3% in the 2nd quarter. Cim Investment Management Inc. now owns 31,172 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 17,399 shares during the period. Long Focus Capital Management LLC raised its holdings in Iovance Biotherapeutics by 195.1% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,132,000 shares of the biotechnology company’s stock valued at $33,139,000 after acquiring an additional 2,731,688 shares during the last quarter. Finally, Dark Forest Capital Management LP purchased a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth $360,000. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Price Performance

IOVA opened at $10.46 on Friday. Iovance Biotherapeutics has a 12 month low of $3.21 and a 12 month high of $18.33. The stock has a market capitalization of $2.93 billion, a P/E ratio of -5.81 and a beta of 0.63. The business has a 50 day simple moving average of $9.36 and a 200-day simple moving average of $11.16.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.01. Iovance Biotherapeutics had a negative return on equity of 65.04% and a negative net margin of 1,343.27%. The company had revenue of $31.11 million during the quarter, compared to the consensus estimate of $24.59 million. During the same quarter last year, the company earned ($0.47) earnings per share. Iovance Biotherapeutics’s quarterly revenue was up 12969.7% compared to the same quarter last year. Research analysts anticipate that Iovance Biotherapeutics will post -1.26 EPS for the current year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.